Literature DB >> 28577031

Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.

Eva Trevisson1, Matteo Cassina2, Enrico Opocher3, Virginia Vicenzi2, Marta Lucchetta4, Raffaele Parrozzani5, Giacomo Miglionico6, Rodica Mardari7, Elisabetta Viscardi3, Edoardo Midena5,6, Maurizio Clementi2.   

Abstract

Optic pathway glioma (OPG) represents the most common central nervous system tumor in children with Neurofibromatosis type-1 (NF1). Although overall survival is usually good, no clear prognostic factors have been identified so far. We assessed the natural history of OPG in a cohort of unselected patients affected by NF1. We retrospectively evaluated 414 consecutive patients affected by NF1 and referred to our NF1 clinic before age 6. Average follow-up was 11.9 years: 52 out of 414 patients had OPG with a total cumulative incidence of 15.4% at age 15 (Kaplan-Meier estimate) and a statistically significant difference according to sex. Brain and orbit MRI was performed in 44.7% of patients: 34.6% for screening purposes and 65.4% because of the presence of neurological, ocular or other symptoms. OPG was diagnosed in 12.5% of cases in the first group, whereas in 36.4% in the latter group (p = 0.001). Clinical management was conservative in most patients, while 8 of them underwent therapy mainly because of visual deterioration. OPG was diagnosed earlier in treated patients, but the difference was not statistically significant. Conversely, all patients who underwent screening MRI had normal visual outcome. In conclusion, OPG location does not correlate with need for treatment; female patients were more frequently affected by OPG but not more frequently treated. OPG diagnosis by screening MRI does not affect the natural history of the tumor.

Entities:  

Keywords:  Brain/orbit MRI; NF1; Neurofibromatosis type 1; Optic pathway glioma

Mesh:

Year:  2017        PMID: 28577031     DOI: 10.1007/s11060-017-2517-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  Spontaneous remission of chiasmatic/hypothalamic masses in neurofibromatosis type 1: report of two cases.

Authors:  S Gottschalk; R Tavakolian; A Buske; S Tinschert; R Lehmann
Journal:  Neuroradiology       Date:  1999-03       Impact factor: 2.804

2.  Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.

Authors:  L J Balcer; G T Liu; G Heller; L Bilaniuk; N J Volpe; S L Galetta; P T Molloy; P C Phillips; A J Janss; S Vaughn; M G Maguire
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

Review 3.  Late-onset optic pathway tumors in children with neurofibromatosis 1.

Authors:  R Listernick; R E Ferner; L Piersall; S Sharif; D H Gutmann; J Charrow
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

4.  Segmental neurofibromatosis in childhood.

Authors:  Robert Listernick; Anthony J Mancini; Joel Charrow
Journal:  Am J Med Genet A       Date:  2003-08-30       Impact factor: 2.802

5.  Emergence of optic pathway gliomas in children with neurofibromatosis type 1 after normal neuroimaging results.

Authors:  R Listernick; J Charrow; M Greenwald
Journal:  J Pediatr       Date:  1992-10       Impact factor: 4.406

Review 6.  Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications.

Authors:  Mohammed F Shamji; Brien G Benoit
Journal:  Neurosurg Focus       Date:  2007       Impact factor: 4.047

Review 7.  Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.

Authors:  Sureka Thiagalingam; Maree Flaherty; Frank Billson; Kathryn North
Journal:  Ophthalmology       Date:  2004-03       Impact factor: 12.079

8.  Optic pathway glioma in children: 10 years of experience in a single institution.

Authors:  Dimitrios Doganis; Apostolos Pourtsidis; Kleonikos Tsakiris; Margarita Baka; Agathi Kouri; Despina Bouhoutsou; Maria Varvoutsi; Marina Servitzoglou; Helen Dana; Helen Kosmidis
Journal:  Pediatr Hematol Oncol       Date:  2016-03-23       Impact factor: 1.969

9.  Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.

Authors:  Allison King; Robert Listernick; Joel Charrow; Linda Piersall; David H Gutmann
Journal:  Am J Med Genet A       Date:  2003-10-01       Impact factor: 2.802

10.  The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.

Authors:  Carlos E Prada; Robert B Hufnagel; Trent R Hummel; Anne M Lovell; Robert J Hopkin; Howard M Saal; Elizabeth K Schorry
Journal:  J Pediatr       Date:  2015-07-29       Impact factor: 6.314

View more
  13 in total

1.  14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019.

Authors: 
Journal:  Neuroophthalmology       Date:  2019-06-07

2.  Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma.

Authors:  Sahaja Acharya; Sophia Quesada; Kenneth Coca; Cody Richardson; Mary E Hoehn; Jason Chiang; Ibrahim Qaddoumi; Frederick A Boop; Amar Gajjar; Thomas E Merchant
Journal:  J Neurooncol       Date:  2019-08-14       Impact factor: 4.130

3.  Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.

Authors:  Laura Sellmer; Said Farschtschi; Marco Marangoni; Manraj K S Heran; Patricia Birch; Ralph Wenzel; Victor-Felix Mautner; Jan M Friedman
Journal:  Orphanet J Rare Dis       Date:  2018-04-23       Impact factor: 4.123

4.  NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation.

Authors:  María Jesús Lobón-Iglesias; Ingrid Laurendeau; Léa Guerrini-Rousseau; Arnault Tauziède-Espariat; Audrey Briand-Suleau; Pascale Varlet; Dominique Vidaud; Michel Vidaud; Laurence Brugieres; Jacques Grill; Eric Pasmant
Journal:  Neurooncol Adv       Date:  2019-12-20

Review 5.  Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations.

Authors:  Matteo Cassina; Luisa Frizziero; Enrico Opocher; Raffaele Parrozzani; Ugo Sorrentino; Elisabetta Viscardi; Giacomo Miglionico; Edoardo Midena; Maurizio Clementi; Eva Trevisson
Journal:  Cancers (Basel)       Date:  2019-11-14       Impact factor: 6.639

6.  Homonymous Retinal Ganglion Cell Layer Atrophy With Asymptomatic Optic Tract Glioma in Neurofibromatosis Type I.

Authors:  Amirah I Momen; Ryan T Muir; Carolina Barnett; Arun N E Sundaram
Journal:  Front Neurol       Date:  2020-04-15       Impact factor: 4.003

7.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

8.  Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1.

Authors:  Stephanie M Morris; Aditi Gupta; Seunghwan Kim; Randi E Foraker; David H Gutmann; Philip R O Payne
Journal:  Neurol Clin Pract       Date:  2021-12

9.  Comparison of two surgical methods for the treatment of optic pathway gliomas in the intraorbital segment: an analysis of long-term clinical follow-up, which evaluates the surgical outcomes.

Authors:  Peng Yang; Hao-Cheng Liu; E Qiu; Wei Wang; Jia-Liang Zhang; Li-Bin Jiang; Jun Kang
Journal:  Transl Pediatr       Date:  2021-06

10.  Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.

Authors:  Johanna Uthoff; Jared Larson; Takashi S Sato; Emily Hammond; Kimberly E Schroeder; Frank Rohret; Christopher S Rogers; Dawn E Quelle; Benjamin W Darbro; Rajesh Khanna; Jill M Weimer; David K Meyerholz; Jessica C Sieren
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.